-
Something wrong with this record ?
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry
T. Spelman, S. Ozakbas, R. Alroughani, M. Terzi, S. Hodgkinson, G. Laureys, T. Kalincik, AV. Der Walt, B. Yamout, J. Lechner-Scott, A. Soysal, J. Kuhle, JL. Sanchez-Menoyo, YB. Morgado, D. Spitaleri, VV. Pesch, D. Horakova, R. Ampapa, F. Patti,...
Language English Country England, Great Britain
Document type Journal Article, Review
PubMed
37287269
DOI
10.2217/nmt-2023-0005
Knihovny.cz E-resources
- MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Cladribine therapeutic use MeSH
- Humans MeSH
- Registries MeSH
- Multiple Sclerosis, Relapsing-Remitting * drug therapy MeSH
- Multiple Sclerosis * drug therapy MeSH
- Tablets MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
WHAT IS THIS SUMMARY ABOUT?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. WHAT DO THE RESULTS MEAN?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.
American University of Beirut Medical Center Beirut Lebanon
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Avellino Italy
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Istanbul Turkey
Center of Neuroimmunology Service of Neurology Hospital Clinic de Barcelona Barcelona Spain
Cliniques Universitaires Saint Luc UCLouvain Brussels Belgium
CORe Department of Medicine University of Melbourne Melbourne Australia
Department of Medical and Surgical Sciences and Advanced Technologies GF Ingrassia Catania Italy
Department of Neurology 19 Mayis University Samsun Turkey
Department of Neurology Austin Health Melbourne Australia
Department of Neurology John Hunter Hospital Hunter New England Health Newcastle Australia
Department of Neuroscience Central Clinical School Monash University Melbourne Australia
Division of Neurology St Michael's Hospital University of Toronto Toronto Canada
Dokuz Eylul University Izmir Turkey
EMD Serono Research and Development Institute Inc Billerica MA USA an affiliate of Merck KGaA
Liverpool Hospital Sydney Australia
MS Centre Department of Neurology Royal Melbourne Hospital Melbourne Australia
MSBase Foundation Melbourne Australia
Nemocnice Jihlava Jihlava Czech Republic
Neurology Institute Harley Street Medical Center Abu Dhabi United Arab Emirates
School for Mental Health and Neuroscience Maastricht University Maastricht The Netherlands
School of Medicine and Public Health University of Newcastle Newcastle Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016719
- 003
- CZ-PrNML
- 005
- 20231026105614.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/nmt-2023-0005 $2 doi
- 035 __
- $a (PubMed)37287269
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Spelman, Tim $u MSBase Foundation, Melbourne, Australia
- 245 12
- $a A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry / $c T. Spelman, S. Ozakbas, R. Alroughani, M. Terzi, S. Hodgkinson, G. Laureys, T. Kalincik, AV. Der Walt, B. Yamout, J. Lechner-Scott, A. Soysal, J. Kuhle, JL. Sanchez-Menoyo, YB. Morgado, D. Spitaleri, VV. Pesch, D. Horakova, R. Ampapa, F. Patti, R. Macdonell, A. Al-Asmi, O. Gerlach, J. Oh, A. Altintas, N. Tundia, SL. Wong, H. Butzkueven, MSBase Study Group
- 520 9_
- $a WHAT IS THIS SUMMARY ABOUT?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. WHAT DO THE RESULTS MEAN?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kladribin $x terapeutické užití $7 D017338
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 650 _2
- $a tablety $7 D013607
- 650 _2
- $a registrace $7 D012042
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ozakbas, Serkan $u Dokuz Eylul University, Izmir, Turkey
- 700 1_
- $a Alroughani, Raed $u Amiri Hospital, Sharq, Kuwait
- 700 1_
- $a Terzi, Murat $u Department of Neurology 19 Mayis University, Samsun, Turkey
- 700 1_
- $a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, Australia
- 700 1_
- $a Laureys, Guy $u University Hospital Ghent, Ghent, Belgium
- 700 1_
- $a Kalincik, Tomas $u MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia $u CORe, Department of Medicine, University of Melbourne, Melbourne, Australia
- 700 1_
- $a Der Walt, Anneke Van $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia
- 700 1_
- $a Yamout, Bassem $u Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates $u American University of Beirut Medical Center, Beirut, Lebanon
- 700 1_
- $a Lechner-Scott, Jeannette $u School of Medicine & Public Health, University of Newcastle, Newcastle, Australia $u Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia
- 700 1_
- $a Soysal, Aysun $u Bakirkoy Education & Research Hospital for Psychiatric & Neurological Diseases, Istanbul, Turkey
- 700 1_
- $a Kuhle, Jens $u Multiple Sclerosis Centre, Neurology, Departments of Head, Spine & Neuromedicine, Biomedicine & Clinical Research, University Hospital Basel & University of Basel, Basel, Switzerland $u Research Center for Clinical Neuroimmunology & Neuroscience (RC2NB), University Hospital & University of Basel, Switzerland
- 700 1_
- $a Sanchez-Menoyo, Jose Luis $u Department of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain
- 700 1_
- $a Morgado, Yolanda Blanco $u Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain
- 700 1_
- $a Spitaleri, Daniele LA $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy
- 700 1_
- $a Pesch, Vincent van $u Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
- 700 1_
- $a Horakova, Dana $u Department of Neurology & Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague & General University Hospital, Prague, Czech Republic
- 700 1_
- $a Ampapa, Radek $u Nemocnice Jihlava, Jihlava, Czech Republic
- 700 1_
- $a Patti, Francesco $u Department of Medical & Surgical Sciences & Advanced Technologies, GF Ingrassia, Catania, Italy
- 700 1_
- $a Macdonell, Richard $u Department of Neurology, Austin Health, Melbourne, Australia
- 700 1_
- $a Al-Asmi, Abdullah $u Neurology Unit, Department of Medicine, College of Medicine & Health Sciences & Sultan Qaboos University Hospital, SQU, Al Khodh, Oman
- 700 1_
- $a Gerlach, Oliver $u Academic MS Center Zuyderland, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands $u School for Mental Health & Neuroscience, Maastricht University, Maastricht, The Netherlands
- 700 1_
- $a Oh, Jiwon $u Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Canada
- 700 1_
- $a Altintas, Ayse $u Koc University School of Medicine & Koc University Research Center for Translational Medicine (KUTTAM) Istanbul, Turkey
- 700 1_
- $a Tundia, Namita $u EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA
- 700 1_
- $a Wong, Schiffon L $u EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA
- 700 1_
- $a Butzkueven, Helmut $u MSBase Foundation, Melbourne, Australia $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia
- 710 2_
- $a MSBase Study Group
- 773 0_
- $w MED00205742 $t Neurodegenerative disease management $x 1758-2032 $g Roč. 13, č. 4 (2023), s. 215-221
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37287269 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105608 $b ABA008
- 999 __
- $a ok $b bmc $g 2000312 $s 1203081
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 13 $c 4 $d 215-221 $e 20230607 $i 1758-2032 $m Neurodegenerative disease management $n Neurodegener Dis Manag $x MED00205742
- LZP __
- $a Pubmed-20231013
